var data={"title":"Lichenoid drug eruption (drug-induced lichen planus)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Lichenoid drug eruption (drug-induced lichen planus)</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/contributors\" class=\"contributor contributor_credentials\">Mirjana Ziemer, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/contributors\" class=\"contributor contributor_credentials\">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 09, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H29641535\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lichenoid drug eruption, also called drug-induced lichen planus, is an uncommon cutaneous adverse effect of several drugs [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/1-4\" class=\"abstract_t\">1-4</a>]. It is characterized by a symmetric eruption of flat-topped, erythematous or violaceous papules resembling lichen planus on the trunk and extremities. The time interval between the initiation of the offending drug and the appearance of the cutaneous lesions varies from months to a year or more and depends upon the class of drug, dose, host reaction, and concurrent medications [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/3\" class=\"abstract_t\">3</a>]. Histologic examination reveals lichenoid interface dermatitis [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/5\" class=\"abstract_t\">5</a>]. </p><p>This topic will discuss the pathogenesis, clinical manifestations, diagnosis, and treatment of lichenoid drug eruptions. Lichen planus and other types of cutaneous adverse reactions to drugs are discussed separately.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">&quot;Lichen planus&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption#H198168284\" class=\"medical medical_review\">&quot;Exanthematous (maculopapular) drug eruption&quot;, section on 'Patient education'</a>.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">&quot;Fixed drug eruption&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">&quot;Drug reaction with eosinophilia and systemic symptoms (DRESS)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acute-generalized-exanthematous-pustulosis-agep\" class=\"medical medical_review\">&quot;Acute generalized exanthematous pustulosis (AGEP)&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">&quot;Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H286117\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence of lichenoid drug eruption is not known. It occurs more frequently in older adults without sex predilection. In small case series, the average age at onset was 44 to 66 years [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/6-8\" class=\"abstract_t\">6-8</a>].</p><p class=\"headingAnchor\" id=\"H29641549\"><span class=\"h1\">ETIOLOGY AND PATHOGENESIS</span></p><p class=\"headingAnchor\" id=\"H29641558\"><span class=\"h2\">Immunologic mechanism</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The pathogenetic mechanism of lichenoid drug reaction is incompletely understood. T cells, keratinocytes, dendritic cells, and endothelial cells, which express activation markers, costimulatory molecules, and adhesion molecules (eg, MHC-class-II molecules, lymphocyte function-associated antigen [LFA] 1, L-selectin, intercellular adhesion molecule [ICAM] 1) are thought to be involved in the inflammatory reaction that ultimately leads to the apoptosis of basal keratinocytes [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/9\" class=\"abstract_t\">9</a>]. </p><p>Both CD4 and CD8 T cells are found at the dermoepidermal junction and within the epidermis. As in lichen planus, a persistent activation of CD8 autocytotoxic T lymphocytes against epidermal cells may be the crucial pathophysiologic factor [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/10\" class=\"abstract_t\">10</a>]. Activated CD8 T cells induce the apoptosis of basal epidermal keratinocytes mainly through the <span class=\"nowrap\">perforin/granzyme</span> B pathway [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/11,12\" class=\"abstract_t\">11,12</a>]. These cells also produce type I and type II cytokines, such as IFN-gamma and IL-5 [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/11-13\" class=\"abstract_t\">11-13</a>]. IFN-gamma induces the expression of MHC-class-II molecules on keratinocytes and facilitates drug binding and presentation to CD4 T cells [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/9\" class=\"abstract_t\">9</a>].</p><p>Plasmacytoid dendritic cells are also thought to be involved in the early phase of lichenoid tissue reaction. They produce large amounts of type I interferons (IFN), such as IFN-alpha, which mediate the activation of IFN-gamma secreting cytotoxic T cells directly or through the maturation of myeloid dendritic cells [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/14\" class=\"abstract_t\">14</a>]. Tumor necrosis factor (TNF)-alpha and other inflammatory cytokines and chemokines are responsible for the amplification of the inflammatory response [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/15-18\" class=\"abstract_t\">15-18</a>]. </p><p class=\"headingAnchor\" id=\"H29641565\"><span class=\"h2\">Medications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lichenoid eruptions have been associated with a broad variety of drugs (<a href=\"image.htm?imageKey=DERM%2F83762\" class=\"graphic graphic_table graphicRef83762 \">table 1</a>), most frequently [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/2-4,6,19-27\" class=\"abstract_t\">2-4,6,19-27</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Angiotensin-converting enzyme (ACE) inhibitors</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thiazide diuretics</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antimalarials</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beta blockers</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gold salts</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">Penicillamine</a></p><p/><p>Lichenoid eruptions involving the oral mucosa have been associated with [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/6,24\" class=\"abstract_t\">6,24</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">Allopurinol</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ACE inhibitors</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Gold salts</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ketoconazole-drug-information\" class=\"drug drug_general\">Ketoconazole</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nonsteroidal anti-inflammatory drugs (NSAIDs)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Anticonvulsants</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Antiretrovirals </p><p/><p>Cases induced by TNF-alpha antagonists (eg, <a href=\"topic.htm?path=infliximab-including-biosimilars-of-infliximab-drug-information\" class=\"drug drug_general\">infliximab</a>, <a href=\"topic.htm?path=adalimumab-including-biosimilars-of-adalimumab-drug-information\" class=\"drug drug_general\">adalimumab</a>, <a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">etanercept</a>, and lenercept) [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/4,23,28\" class=\"abstract_t\">4,23,28</a>] and tyrosine kinase inhibitor <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> mesylate [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/29-33\" class=\"abstract_t\">29-33</a>] have also been reported. A papular lichenoid eruption with histopathologic features of lichenoid interface dermatitis has been reported in several cancer patients treated with antagonist antibodies to programmed cell death 1 (<a href=\"topic.htm?path=nivolumab-drug-information\" class=\"drug drug_general\">nivolumab</a> and <a href=\"topic.htm?path=pembrolizumab-drug-information\" class=\"drug drug_general\">pembrolizumab</a>) or programmed cell death ligand 1 (<a href=\"topic.htm?path=atezolizumab-drug-information\" class=\"drug drug_general\">atezolizumab</a>) [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/34-37\" class=\"abstract_t\">34-37</a>].</p><p class=\"headingAnchor\" id=\"H29641572\"><span class=\"h2\">Latency</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The latency period between drug initiation and appearance of the eruption varies from months to a year or more and depends upon the type of drug, dosage, host reaction, previous exposure to the drug, and concurrent medications [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/3\" class=\"abstract_t\">3</a>].</p><p>A latency period of two months to three years has been reported for <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">penicillamine</a>, three to six months for ACE inhibitors, and four to six weeks for quinacrine [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/25-27\" class=\"abstract_t\">25-27</a>]. </p><p class=\"headingAnchor\" id=\"H29641579\"><span class=\"h2\">Contribution of ultraviolet irradiation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Photosensitive lichenoid eruptions have been reported in patients taking a variety of drugs, in particular [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/6,38-41\" class=\"abstract_t\">6,38-41</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thiazide diuretics </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=diltiazem-drug-information\" class=\"drug drug_general\">Diltiazem</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=quinine-drug-information\" class=\"drug drug_general\">Quinine</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=quinidine-drug-information\" class=\"drug drug_general\">Quinidine</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Tetracyclines </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=ethambutol-drug-information\" class=\"drug drug_general\">Ethambutol</a></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=chlorpromazine-drug-information\" class=\"drug drug_general\">Chlorpromazine</a> </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=carbamazepine-drug-information\" class=\"drug drug_general\">Carbamazepine</a></p><p/><p>The action spectrum for these drugs appears to be in the ultraviolet B (UVB) wavelength range (290 to 320 nm) [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/41,42\" class=\"abstract_t\">41,42</a>].</p><p class=\"headingAnchor\" id=\"H29641593\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span></p><p class=\"headingAnchor\" id=\"H29641602\"><span class=\"h2\">Skin lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lichenoid drug eruption is characterized by a symmetric eruption of flat-topped, erythematous or violaceous papules, often grouped and confluent, on the trunk and extremities (<a href=\"image.htm?imageKey=DERM%2F83767%7EDERM%2F83768\" class=\"graphic graphic_picture graphicRef83767 graphicRef83768 \">picture 1A-B</a>). Lesions closely resemble those seen in lichen planus (<a href=\"image.htm?imageKey=DERM%2F76383%7EDERM%2F50632\" class=\"graphic graphic_picture graphicRef76383 graphicRef50632 \">picture 2A-B</a>), although in lichenoid drug eruption the individual lesions are less monomorphic and may have eczematous or psoriasiform morphology with marked desquamation [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/43\" class=\"abstract_t\">43</a>]. Wickham striae (<a href=\"image.htm?imageKey=PC%2F61523\" class=\"graphic graphic_picture graphicRef61523 \">picture 3</a>), consisting of fine, white lacelike patterns highly characteristic of lichen planus, are usually absent, but their presence does not exclude a drug-related etiology [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/43\" class=\"abstract_t\">43</a>]. </p><p>The eruption can be localized or generalized, with a fairly symmetrical distribution. In some patients, the lesions are localized to the photoexposed areas and exhibit photoaggravation. In contrast to lichen planus, the lesions of lichenoid drug eruption are distributed on the extensor aspects of the extremities and dorsal aspects of the hands (<a href=\"image.htm?imageKey=DERM%2F76383%7EDERM%2F83769%7EDERM%2F59258\" class=\"graphic graphic_picture graphicRef76383 graphicRef83769 graphicRef59258 \">picture 2A, 2C-D</a>) [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/21\" class=\"abstract_t\">21</a>]. Nails are usually spared.</p><p>Pruritus is frequent, although some patients are completely asymptomatic. </p><p class=\"headingAnchor\" id=\"H29641609\"><span class=\"h2\">Oral lesions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral lichenoid drug eruptions are rare. The lesions are identical to those of oral lichen planus and may have an erosive or reticular morphology (<a href=\"image.htm?imageKey=DERM%2F83774\" class=\"graphic graphic_picture graphicRef83774 \">picture 4</a>). Erosive lesions are associated with pain, burning, and irritation. Reticular forms are usually asymptomatic. Oral lichenoid drug eruptions have been associated with several drugs, including <a href=\"topic.htm?path=allopurinol-drug-information\" class=\"drug drug_general\">allopurinol</a>, angiotensin-converting enzyme (ACE) inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and antiretrovirals [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/6,24\" class=\"abstract_t\">6,24</a>]. </p><p class=\"headingAnchor\" id=\"H71523368\"><span class=\"h1\">CLINICAL COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The eruption resolves in weeks to months after the discontinuation of the offending drug, leaving postinflammatory hyperpigmentation (<a href=\"image.htm?imageKey=DERM%2F83771\" class=\"graphic graphic_picture graphicRef83771 \">picture 5</a>). Occasionally, the eruption disappears or recurs intermittently despite continuation of treatment [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/44,45\" class=\"abstract_t\">44,45</a>]. </p><p class=\"headingAnchor\" id=\"H29641623\"><span class=\"h1\">PATHOLOGY</span></p><p class=\"headingAnchor\" id=\"H29641632\"><span class=\"h2\">Histopathologic findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histologically, lichenoid drug eruption is an interface dermatitis. Lichenoid interface dermatitis is a nonspecific reaction pattern occurring in idiopathic lichen planus and other lichenoid eruptions (eg, lichenoid purpura, cutaneous graft-versus-host disease, pityriasis lichenoides chronica, discoid lupus erythematosus, fixed drug eruption) [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/5\" class=\"abstract_t\">5</a>]. Lichenoid interface dermatitis also may be found in some cases of maculopapular drug reactions.</p><p>Major pathologic findings seen in both lichenoid drug eruption and lichen planus include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Damage of basal epidermal keratinocytes with multiple apoptotic cells (colloid or Civatte bodies) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A band-like lymphocytic infiltrate in the papillary dermis that obscures the dermoepidermal junction</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pigmentary incontinence with dermal melanophages</p><p/><p>Findings that are more typical of lichenoid drug eruption than lichen planus include (<a href=\"image.htm?imageKey=DERM%2F83936\" class=\"graphic graphic_table graphicRef83936 \">table 2</a> and <a href=\"image.htm?imageKey=DERM%2F83937\" class=\"graphic graphic_picture graphicRef83937 \">picture 6</a>) [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/8,21\" class=\"abstract_t\">8,21</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Focal parakeratosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Focal interruption of the granular layer</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Cytoid bodies in the cornified and granular layers</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Presence of eosinophils </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A higher number of necrotic keratinocytes, sometimes in clusters, as well as plasma cells and eosinophils</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Exocytosis of lymphoid cells into the upper epidermis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Deeper perivascular infiltrate</p><p/><p>These features are seen more often in non-photodistributed lesions. Photodistributed lesions are usually indistinguishable from idiopathic lichen planus. </p><p class=\"headingAnchor\" id=\"H29641639\"><span class=\"h2\">Direct immunofluorescence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Direct immunofluorescence shows globular deposits of IgM and occasionally IgG and IgA at the dermoepidermal junction and in the lower epidermis. Shaggy deposition of fibrinogen at the dermoepidermal junction is also seen. As in lichen planus, marked cytoid body staining may be present in most cases [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/46\" class=\"abstract_t\">46</a>]. </p><p class=\"headingAnchor\" id=\"H29641646\"><span class=\"h2\">Immunohistochemical studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunohistochemical studies show that the majority of the cells in the infiltrate at the dermoepidermal interface are CD4 and autoreactive CD8 effector T cells. In contrast to idiopathic lichen planus, in lichenoid drug reaction a correlation has been found between the number of T cells and CD8<sup>+</sup> cells and between the number of granzyme B<sup>+</sup> cells and necrotic keratinocytes [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/8\" class=\"abstract_t\">8</a>]. Immunohistochemical staining is not routinely performed for the diagnosis of lichenoid skin eruption.</p><p class=\"headingAnchor\" id=\"H29641653\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of lichenoid drug eruption is based upon a combination of the following findings: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Clinical features </strong>&ndash;<strong> </strong>Symmetric eruption of flat-topped, erythematous or violaceous papules, often grouped and confluent, resembling lichen planus on the trunk and extremities (<a href=\"image.htm?imageKey=DERM%2F83767%7EDERM%2F83768%7EDERM%2F83769\" class=\"graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769 \">picture 1A-B, 2C</a>). (See <a href=\"#H29641602\" class=\"local\">'Skin lesions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Evaluation of a skin biopsy</strong> &ndash; Histologic findings of interface dermatitis with a band-like lymphocytic infiltrate and other histopathologic features more characteristic of lichenoid drug eruption (<a href=\"image.htm?imageKey=DERM%2F83937\" class=\"graphic graphic_picture graphicRef83937 \">picture 6</a>). (See <a href=\"#H29641632\" class=\"local\">'Histopathologic findings'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Medication history</strong> &ndash; Evidence of temporal relationship between drug intake and development of skin lesions. The assessment of a temporal relationship between drug intake and onset of the eruption may be difficult because of the wide variability in the latency time, particularly in patients on multiple medications. (See <a href=\"#H29641572\" class=\"local\">'Latency'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Clinical course</strong> &ndash; Resolution upon drug withdrawal and recurrence upon rechallenge.</p><p/><p>Patch testing with the patient's drugs has been used to try to determine the offending agent in patients with various types of cutaneous drug reactions and in patients with oral lichen planus [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/47-49\" class=\"abstract_t\">47-49</a>]. However, patch testing is not routinely performed in patients with suspected lichenoid drug eruptions because false negative results are frequent. In small observational studies only 30 to 50 percent of patients with cutaneous drug reactions had positive or clinically relevant patch tests [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/47-49\" class=\"abstract_t\">47-49</a>]. </p><p class=\"headingAnchor\" id=\"H29641676\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Conditions that should be considered in the differential diagnosis of lichenoid drug eruption include: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lichen planus</strong> &ndash; The cutaneous lesions of lichen planus are shiny, flat, polygonal, violaceous papules (<a href=\"image.htm?imageKey=PC%2F70518%7EDERM%2F58361%7EDERM%2F50632\" class=\"graphic graphic_picture graphicRef70518 graphicRef58361 graphicRef50632 \">picture 2B, 2E-F</a>); the morphology is similar to that of lichenoid drug eruption. However, in lichen planus, fine, white lacelike patterns known as Wickham striae are present over the surface of many papules (<a href=\"image.htm?imageKey=PC%2F61523\" class=\"graphic graphic_picture graphicRef61523 \">picture 3</a>). Moreover, the lesions of idiopathic lichen planus are typically distributed symmetrically over the extremities and tend to involve the flexural areas of wrists, arms, and legs (<a href=\"image.htm?imageKey=DERM%2F76383\" class=\"graphic graphic_picture graphicRef76383 \">picture 2A</a>), whereas in lichenoid drug eruption the lesions typically occur on the trunk and extensor surfaces. Oral involvement is common in lichen planus and less so in lichenoid drug eruption. The histopathologic differential diagnosis of lichen planus and lichenoid drug eruption is summarized in the table (<a href=\"image.htm?imageKey=DERM%2F83936\" class=\"graphic graphic_table graphicRef83936 \">table 2</a>). (See <a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">&quot;Lichen planus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Lupus erythematosus </strong>&ndash; On histology, a lichenoid interface dermatitis may be seen in some cases of chronic cutaneous lupus erythematosus. In contrast to lichenoid drug eruption, lesions of lupus erythematosus show a moderately dense perivascular and periappendageal lymphocytic infiltrate in the papillary and reticular dermis, with abundant mucin deposits in the latter. There is focal or continuous epidermal thinning, smudged appearance of the dermoepidermal junction with vacuolar degeneration of basal cells, individual necrotic keratinocytes, and a thickened basal membrane zone. Direct immunofluorescence reveals a band-like deposition of IgG and IgM along the basement membrane zone in most cases. (See <a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">&quot;Overview of cutaneous lupus erythematosus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Giant cell lichenoid dermatitis</strong> &ndash; Giant cell lichenoid dermatitis is a rare condition considered an unusual variant of lichenoid drug eruption or a manifestation of sarcoidosis [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/50\" class=\"abstract_t\">50</a>]. Histopathologic findings include focal vacuolar alteration of the basal layer with cytoid bodies, dermal and intraepidermal multinucleated giant cells, and a chronic inflammatory infiltrate consisting of lymphocytes, eosinophils, plasma cells, and macrophages.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Keratosis lichenoides chronica</strong> &ndash; Keratosis lichenoides chronica is a rare disorder characterized by violaceous, tiny papules centered on hair infundibula and sweat ducts and arranged in a linear and reticulate pattern [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/51,52\" class=\"abstract_t\">51,52</a>]. Histologically, there is a lichenoid infiltrate with focal epidermal acanthosis and atrophy. </p><p/><p class=\"headingAnchor\" id=\"H29641683\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H38715886\"><span class=\"h2\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lichenoid drug eruptions generally resolve spontaneously a few weeks to a few months after the discontinuation of the offending drug [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/6,53\" class=\"abstract_t\">6,53</a>]. However, treatment may be warranted in the following situations: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who cannot discontinue the offending drug</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prolonged disease (ie, persistent lesions several months after discontinuation of the drug) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Extensive disease (eg, involving the trunk and extremities) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Symptoms (eg, pruritus)</p><p/><p class=\"headingAnchor\" id=\"H64668815\"><span class=\"h2\">Cutaneous eruption</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment options include topical or systemic corticosteroids and oral retinoids. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with symptomatic disease involving a limited skin area (eg, the extremities), we suggest topical corticosteroids rather than oral corticosteroids. We generally use a superpotent topical corticosteroid (eg, <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> propionate 0.05%, <a href=\"topic.htm?path=fluocinonide-drug-information\" class=\"drug drug_general\">fluocinonide</a> 0.05%) ointment or cream twice daily for two to four weeks.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with extensive, symptomatic disease, we suggest oral corticosteroids rather than topical corticosteroids or oral retinoids. We generally use <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">Acitretin</a> 25 to 35 mg per day for six to twelve weeks is an alternative for patients in whom systemic corticosteroids are contraindicated. </p><p/><p>The efficacy of topical corticosteroids, systemic corticosteroids, and <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">acitretin</a> for lichenoid drug eruption has not been evaluated in randomized trials. Their use is based upon clinical experience and limited evidence of efficacy from a few small clinical studies in patients with idiopathic lichen planus [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/54-56\" class=\"abstract_t\">54-56</a>]. (See <a href=\"topic.htm?path=lichen-planus#H9\" class=\"medical medical_review\">&quot;Lichen planus&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H64668843\"><span class=\"h2\">Oral eruption</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The reticular form of oral lichenoid drug eruption is generally asymptomatic and does not require treatment. Topical or oral corticosteroids are used for the treatment of the erosive form to reduce pain and discomfort and hasten healing. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with oral erosive lichenoid drug eruption, we suggest topical corticosteroids as first line treatment. We typically use a superpotent topical corticosteroid (eg, <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> propionate 0.05% ointment) two or three times per day for four to eight weeks.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with oral erosive lichenoid drug eruption that does not respond to topical corticosteroids, we suggest oral corticosteroids. We generally use <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> at a dose of 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. </p><p/><p>The efficacy of topical and oral corticosteroids for the treatment of oral erosive lichenoid drug eruption has not been evaluated in randomized trials. Their use is based upon clinical experience and limited evidence of efficacy from randomized trials in idiopathic oral lichen planus [<a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/57,58\" class=\"abstract_t\">57,58</a>]. (See <a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">&quot;Lichen planus&quot;</a> and <a href=\"topic.htm?path=oral-lichen-planus-management-and-prognosis\" class=\"medical medical_review\">&quot;Oral lichen planus: Management and prognosis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H29641690\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lichenoid drug eruption, also called drug-induced lichen planus, is an uncommon cutaneous adverse effect of several drugs. (See <a href=\"#H29641535\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The drugs most frequently reported are angiotensin-converting enzyme (ACE) inhibitors, thiazide diuretics, antimalarials, beta blockers, gold salts, and <a href=\"topic.htm?path=penicillamine-drug-information\" class=\"drug drug_general\">penicillamine</a> (<a href=\"image.htm?imageKey=DERM%2F83762\" class=\"graphic graphic_table graphicRef83762 \">table 1</a>). The latency period between the drug initiation and the appearance of the eruption varies from months to a year or more. (See <a href=\"#H29641565\" class=\"local\">'Medications'</a> above and <a href=\"#H29641572\" class=\"local\">'Latency'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lichenoid drug eruption manifests with a symmetric eruption of erythematous or violaceous, flat-topped polygonal papules, often grouped and confluent. They have eczematous or psoriasiform morphology with marked desquamation. The eruption involves the trunk and extensor aspects of the extremities (<a href=\"image.htm?imageKey=DERM%2F83767%7EDERM%2F83768%7EDERM%2F83769%7EDERM%2F59258\" class=\"graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769 graphicRef59258 \">picture 1A-B, 2C-D</a>). (See <a href=\"#H29641602\" class=\"local\">'Skin lesions'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of lichenoid drug eruption is based upon a combination of the following findings (see <a href=\"#H29641653\" class=\"local\">'Diagnosis'</a> above):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Clinical findings of a symmetric eruption of flat-topped, erythematous or violaceous papules resembling lichen planus on the trunk and extremities (<a href=\"image.htm?imageKey=DERM%2F83767%7EDERM%2F83768%7EDERM%2F83769\" class=\"graphic graphic_picture graphicRef83767 graphicRef83768 graphicRef83769 \">picture 1A-B, 2C</a>)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Histologic findings of interface dermatitis with a band-like lymphocytic infiltrate (<a href=\"image.htm?imageKey=DERM%2F83937\" class=\"graphic graphic_picture graphicRef83937 \">picture 6</a>) (see <a href=\"#H29641632\" class=\"local\">'Histopathologic findings'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Temporal relationship between drug intake and development of skin lesions</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Resolution upon drug withdrawal and recurrence upon rechallenge</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lichenoid drug eruptions generally resolve spontaneously a few weeks to a few months after the discontinuation of the offending drug. Treatment may be warranted in patients who cannot discontinue the offending drug or have symptomatic or extensive disease. (See <a href=\"#H38715886\" class=\"local\">'Indications'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with symptomatic disease involving a limited skin area (eg, the extremities), we suggest topical corticosteroids rather than oral corticosteroids (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We generally use <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> propionate 0.05% or <a href=\"topic.htm?path=fluocinonide-drug-information\" class=\"drug drug_general\">fluocinonide</a> 0.05% ointment or cream twice daily for two to four weeks. (See <a href=\"#H64668815\" class=\"local\">'Cutaneous eruption'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with extensive, symptomatic disease, we suggest oral corticosteroids rather than topical corticosteroids or oral retinoids (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We generally use <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. <a href=\"topic.htm?path=acitretin-drug-information\" class=\"drug drug_general\">Acitretin</a> 25 to 35 mg per day for six to twelve weeks is an alternative for patients in whom systemic corticosteroids are contraindicated. (See <a href=\"#H64668815\" class=\"local\">'Cutaneous eruption'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patient with oral erosive lichenoid drug eruption, we suggest topical corticosteroids as first line treatment (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We typically use <a href=\"topic.htm?path=clobetasol-drug-information\" class=\"drug drug_general\">clobetasol</a> propionate 0.05% ointment two or three times per day for four to eight weeks. (See <a href=\"#H64668843\" class=\"local\">'Oral eruption'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with oral erosive lichenoid drug eruption that does not respond to topical corticosteroids, we suggest oral corticosteroids (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We generally use <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> at a dose of 30 to 60 mg per day for two to six weeks. Prednisone is then tapered over the next two to six weeks. (See <a href=\"#H64668843\" class=\"local\">'Oral eruption'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/1\" class=\"nounderline abstract_t\">Fox GN, Harrell CC, Mehregan DR. Extensive lichenoid drug eruption due to glyburide: a case report and review of the literature. Cutis 2005; 76:41.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/2\" class=\"nounderline abstract_t\">Antiga E, Melani L, Cardinali C, et al. A case of lichenoid drug eruption associated with sildenafil citratus. J Dermatol 2005; 32:972.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/3\" class=\"nounderline abstract_t\">Brauer J, Votava HJ, Meehan S, Soter NA. Lichenoid drug eruption. Dermatol Online J 2009; 15:13.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/4\" class=\"nounderline abstract_t\">Asarch A, Gottlieb AB, Lee J, et al. Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonists. J Am Acad Dermatol 2009; 61:104.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/5\" class=\"nounderline abstract_t\">Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129:1088.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/6\" class=\"nounderline abstract_t\">Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29:249.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/7\" class=\"nounderline abstract_t\">West AJ, Berger TG, LeBoit PE. A comparative histopathologic study of photodistributed and nonphotodistributed lichenoid drug eruptions. J Am Acad Dermatol 1990; 23:689.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/8\" class=\"nounderline abstract_t\">Lage D, Juliano PB, Metze K, et al. Lichen planus and lichenoid drug-induced eruption: a histological and immunohistochemical study. Int J Dermatol 2012; 51:1199.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/9\" class=\"nounderline abstract_t\">Yawalkar N, Pichler WJ. [Mechanisms of cutaneous drug reactions]. J Dtsch Dermatol Ges 2004; 2:1013.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/10\" class=\"nounderline abstract_t\">Sugerman PB, Satterwhite K, Bigby M. Autocytotoxic T-cell clones in lichen planus. Br J Dermatol 2000; 142:449.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/11\" class=\"nounderline abstract_t\">Yawalkar N, Pichler WJ. Immunohistology of drug-induced exanthema: clues to pathogenesis. Curr Opin Allergy Clin Immunol 2001; 1:299.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/12\" class=\"nounderline abstract_t\">Yawalkar N, Egli F, Hari Y, et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30:847.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/13\" class=\"nounderline abstract_t\">Yawalkar N, Shrikhande M, Hari Y, et al. Evidence for a role for IL-5 and eotaxin in activating and recruiting eosinophils in drug-induced cutaneous eruptions. J Allergy Clin Immunol 2000; 106:1171.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/14\" class=\"nounderline abstract_t\">Meller S, Gilliet M, Homey B. Chemokines in the pathogenesis of lichenoid tissue reactions. J Invest Dermatol 2009; 129:315.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/15\" class=\"nounderline abstract_t\">Wenzel J, Scheler M, Proelss J, et al. Type I interferon-associated cytotoxic inflammation in lichen planus. J Cutan Pathol 2006; 33:672.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/16\" class=\"nounderline abstract_t\">Erdem MT, Gulec AI, Kiziltunc A, et al. Increased serum levels of tumor necrosis factor alpha in lichen planus. Dermatology 2003; 207:367.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/17\" class=\"nounderline abstract_t\">Akasu R, From L, Kahn HJ. Lymphocyte and macrophage subsets in active and inactive lesions of lichen planus. Am J Dermatopathol 1993; 15:217.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/18\" class=\"nounderline abstract_t\">Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol 2007; 143:233.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/19\" class=\"nounderline abstract_t\">Teraki Y, Shiohara T. Spontaneous tolerance to terbinafine-induced lichenoid drug eruption. Dermatology 2004; 208:81.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/20\" class=\"nounderline abstract_t\">Bong JL, Lucke TW, Douglas WS. Lichenoid drug eruption with proton pump inhibitors. BMJ 2000; 320:283.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/21\" class=\"nounderline abstract_t\">Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 1989; 179:10.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/22\" class=\"nounderline abstract_t\">De Simone C, Caldarola G, D'Agostino M, et al. Lichenoid reaction induced by adalimumab. J Eur Acad Dermatol Venereol 2008; 22:626.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/23\" class=\"nounderline abstract_t\">Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002; 138:1258.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/24\" class=\"nounderline abstract_t\">Woo V, Bonks J, Borukhova L, Zegarelli D. Oral lichenoid drug eruption: a report of a pediatric case and review of the literature. Pediatr Dermatol 2009; 26:458.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/25\" class=\"nounderline abstract_t\">Powell FC, Rogers RS 3rd, Dickson ER. Primary biliary cirrhosis and lichen planus. J Am Acad Dermatol 1983; 9:540.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/26\" class=\"nounderline abstract_t\">Rotstein E, Rotstein H. Drug eruptions with lichenoid histology produced by captopril. Australas J Dermatol 1989; 30:9.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/27\" class=\"nounderline abstract_t\">Bauer F. Quinacrine hydrochloride drug eruption (tropical lichenoid dermatitis). Its early and late sequelae and its malignant potential: a review. J Am Acad Dermatol 1981; 4:239.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/28\" class=\"nounderline abstract_t\">Garcovich S, Manco S, Zampetti A, et al. Onset of lichen planopilaris during treatment with etanercept. Br J Dermatol 2008; 158:1161.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/29\" class=\"nounderline abstract_t\">Wahiduzzaman M, Pubalan M. Oral and cutaneous lichenoid reaction with nail changes secondary to imatinib: report of a case and literature review. Dermatol Online J 2008; 14:14.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/30\" class=\"nounderline abstract_t\">Luo JR, Xiang XJ, Xiong JP. Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor. Int J Clin Pharmacol Ther 2016; 54:719.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/31\" class=\"nounderline abstract_t\">Bhatia A, Kanish B, Chaudhary P. Lichenoid drug eruption due to imatinib mesylate. Int J Appl Basic Med Res 2015; 5:68.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/32\" class=\"nounderline abstract_t\">Kagimoto Y, Mizuashi M, Kikuchi K, Aiba S. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate. Int J Dermatol 2014; 53:e161.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/33\" class=\"nounderline abstract_t\">Inoue A, Sawada Y, Yamaguchi T, et al. Lichenoid drug eruption caused by adalimumab: a case report and literature review. Eur J Dermatol 2017; 27:69.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/34\" class=\"nounderline abstract_t\">Shi VJ, Rodic N, Gettinger S, et al. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti-Programmed Cell Death 1 and Anti-Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatol 2016; 152:1128.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/35\" class=\"nounderline abstract_t\">Goldinger SM, Stieger P, Meier B, et al. Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy. Clin Cancer Res 2016; 22:4023.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/36\" class=\"nounderline abstract_t\">Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol 2016; 43:339.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/37\" class=\"nounderline abstract_t\">Kratzsch D, Simon JC, Ziemer M. Lichen planus-like drug eruption on anti-PD-1 therapy. J Dtsch Dermatol Ges 2017; 15:1238.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/38\" class=\"nounderline abstract_t\">HARBER LC, LASHINSKY AM, BAER RL. Photosensitivity due to chlorothiazide and hydrochlorothiazide. N Engl J Med 1959; 261:1378.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/39\" class=\"nounderline abstract_t\">Kubo Y, Fukumoto D, Ishigami T, et al. Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review. J Dermatol 2010; 37:807.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/40\" class=\"nounderline abstract_t\">Johnston GA. Thiazide-induced lichenoid photosensitivity. Clin Exp Dermatol 2002; 27:670.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/41\" class=\"nounderline abstract_t\">Stein KR, Scheinfeld NS. Drug-induced photoallergic and phototoxic reactions. Expert Opin Drug Saf 2007; 6:431.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/42\" class=\"nounderline abstract_t\">Moore DE. Drug-induced cutaneous photosensitivity: incidence, mechanism, prevention and management. Drug Saf 2002; 25:345.</a></li><li class=\"breakAll\">Bork K. Lichenoid eruptions. In: Cutaneous Side Effects of Drugs, Bork K (Ed), WB Saunders, Philadelphia 1988. p.170.</li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/44\" class=\"nounderline abstract_t\">Anderson TE. Lichen planus following quinidine therapy. Br J Dermatol 1967; 79:500.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/45\" class=\"nounderline abstract_t\">Seehafer JR, Rogers RS 3rd, Fleming CR, Dickson ER. Lichen planus-like lesions caused by penicillamine in primary biliary cirrhosis. Arch Dermatol 1981; 117:140.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/46\" class=\"nounderline abstract_t\">Oliver GF, Winkelmann RK, Muller SA. Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases. J Am Acad Dermatol 1989; 21:284.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/47\" class=\"nounderline abstract_t\">Barbaud A, Gon&ccedil;alo M, Bruynzeel D, et al. Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis 2001; 45:321.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/48\" class=\"nounderline abstract_t\">Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209:209.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/49\" class=\"nounderline abstract_t\">Lomaga MA, Polak S, Grushka M, Walsh S. Results of patch testing in patients diagnosed with oral lichen planus. J Cutan Med Surg 2009; 13:88.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/50\" class=\"nounderline abstract_t\">Khelifa-Hamdani E, Touati-Serraj M, Perriard J, et al. Giant cell lichenoid dermatitis in a patient with baboon syndrome. J Cutan Pathol 2008; 35 Suppl 1:17.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/51\" class=\"nounderline abstract_t\">B&ouml;er A. Keratosis lichenoides chronica: proposal of a concept. Am J Dermatopathol 2006; 28:260.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/52\" class=\"nounderline abstract_t\">Konstantinov KN, S&oslash;ndergaard J, Izuno G, Obreshkova E. Keratosis lichenoides chronica. J Am Acad Dermatol 1998; 38:306.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/53\" class=\"nounderline abstract_t\">Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol 1998; 16:325.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/54\" class=\"nounderline abstract_t\">Cribier B, Frances C, Chosidow O. Treatment of lichen planus. An evidence-based medicine analysis of efficacy. Arch Dermatol 1998; 134:1521.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/55\" class=\"nounderline abstract_t\">Laurberg G, Geiger JM, Hjorth N, et al. Treatment of lichen planus with acitretin. A double-blind, placebo-controlled study in 65 patients. J Am Acad Dermatol 1991; 24:434.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/56\" class=\"nounderline abstract_t\">Le Cleach L, Chosidow O. Clinical practice. Lichen planus. N Engl J Med 2012; 366:723.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/57\" class=\"nounderline abstract_t\">Cheng S, Kirtschig G, Cooper S, et al. Interventions for erosive lichen planus affecting mucosal sites. Cochrane Database Syst Rev 2012; :CD008092.</a></li><li><a href=\"https://www.uptodate.com/contents/lichenoid-drug-eruption-drug-induced-lichen-planus/abstract/58\" class=\"nounderline abstract_t\">Thongprasom K, Carrozzo M, Furness S, Lodi G. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2011; :CD001168.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15763 Version 7.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H29641690\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H29641535\" id=\"outline-link-H29641535\">INTRODUCTION</a></li><li><a href=\"#H286117\" id=\"outline-link-H286117\">EPIDEMIOLOGY</a></li><li><a href=\"#H29641549\" id=\"outline-link-H29641549\">ETIOLOGY AND PATHOGENESIS</a><ul><li><a href=\"#H29641558\" id=\"outline-link-H29641558\">Immunologic mechanism</a></li><li><a href=\"#H29641565\" id=\"outline-link-H29641565\">Medications</a></li><li><a href=\"#H29641572\" id=\"outline-link-H29641572\">Latency</a></li><li><a href=\"#H29641579\" id=\"outline-link-H29641579\">Contribution of ultraviolet irradiation</a></li></ul></li><li><a href=\"#H29641593\" id=\"outline-link-H29641593\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H29641602\" id=\"outline-link-H29641602\">Skin lesions</a></li><li><a href=\"#H29641609\" id=\"outline-link-H29641609\">Oral lesions</a></li></ul></li><li><a href=\"#H71523368\" id=\"outline-link-H71523368\">CLINICAL COURSE</a></li><li><a href=\"#H29641623\" id=\"outline-link-H29641623\">PATHOLOGY</a><ul><li><a href=\"#H29641632\" id=\"outline-link-H29641632\">Histopathologic findings</a></li><li><a href=\"#H29641639\" id=\"outline-link-H29641639\">Direct immunofluorescence</a></li><li><a href=\"#H29641646\" id=\"outline-link-H29641646\">Immunohistochemical studies</a></li></ul></li><li><a href=\"#H29641653\" id=\"outline-link-H29641653\">DIAGNOSIS</a></li><li><a href=\"#H29641676\" id=\"outline-link-H29641676\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H29641683\" id=\"outline-link-H29641683\">TREATMENT</a><ul><li><a href=\"#H38715886\" id=\"outline-link-H38715886\">Indications</a></li><li><a href=\"#H64668815\" id=\"outline-link-H64668815\">Cutaneous eruption</a></li><li><a href=\"#H64668843\" id=\"outline-link-H64668843\">Oral eruption</a></li></ul></li><li><a href=\"#H29641690\" id=\"outline-link-H29641690\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15763|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/83767\" class=\"graphic graphic_picture\">- Lichenoid drug eruption 1</a></li><li><a href=\"image.htm?imageKey=DERM/83768\" class=\"graphic graphic_picture\">- Lichenoid drug eruption 2</a></li><li><a href=\"image.htm?imageKey=DERM/76383\" class=\"graphic graphic_picture\">- Lichen planus wrists fair skin</a></li><li><a href=\"image.htm?imageKey=DERM/50632\" class=\"graphic graphic_picture\">- Generalized lichen planus</a></li><li><a href=\"image.htm?imageKey=PC/61523\" class=\"graphic graphic_picture\">- Wickhams striae on plaque</a></li><li><a href=\"image.htm?imageKey=DERM/83769\" class=\"graphic graphic_picture\">- Lichenoid drug eruption hand</a></li><li><a href=\"image.htm?imageKey=DERM/59258\" class=\"graphic graphic_picture\">- Lichenoid drug eruption hyperpigmentation</a></li><li><a href=\"image.htm?imageKey=DERM/83774\" class=\"graphic graphic_picture\">- Lichenoid drug eruption oral</a></li><li><a href=\"image.htm?imageKey=DERM/83771\" class=\"graphic graphic_picture\">- Lichenoid drug eruption hyperpigmentation 2</a></li><li><a href=\"image.htm?imageKey=DERM/83937\" class=\"graphic graphic_picture\">- Lichenoid interface dermatitis</a></li><li><a href=\"image.htm?imageKey=PC/70518\" class=\"graphic graphic_picture\">- Lichen planus arm</a></li><li><a href=\"image.htm?imageKey=DERM/58361\" class=\"graphic graphic_picture\">- Lichen planus hand</a></li></ul></li><li><div id=\"DERM/15763|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/83762\" class=\"graphic graphic_table\">- Drugs causing lichenoid eruptions</a></li><li><a href=\"image.htm?imageKey=DERM/83936\" class=\"graphic graphic_table\">- Lichenoid drug eruption histology differential</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-generalized-exanthematous-pustulosis-agep\" class=\"medical medical_review\">Acute generalized exanthematous pustulosis (AGEP)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-reaction-with-eosinophilia-and-systemic-symptoms-dress\" class=\"medical medical_review\">Drug reaction with eosinophilia and systemic symptoms (DRESS)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=exanthematous-maculopapular-drug-eruption\" class=\"medical medical_review\">Exanthematous (maculopapular) drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=fixed-drug-eruption\" class=\"medical medical_review\">Fixed drug eruption</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lichen-planus\" class=\"medical medical_review\">Lichen planus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-lichen-planus-management-and-prognosis\" class=\"medical medical_review\">Oral lichen planus: Management and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-cutaneous-lupus-erythematosus\" class=\"medical medical_review\">Overview of cutaneous lupus erythematosus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stevens-johnson-syndrome-and-toxic-epidermal-necrolysis-management-prognosis-and-long-term-sequelae\" class=\"medical medical_review\">Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae</a></li></ul></div></div>","javascript":null}